Restart Life Sciences Corp.
HEAL
Rangering i aksjer
#35834
Operating internationally through its various subsidiaries, Restart Life... Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Aksjekurs
$0.05137558
Sist synkronisert: 2026-10-16
Markedsverdi
$3.21M
Endring (1 dag)
0.00%
Endring (1 år)
78.84%
Land
CA
Handel Restart Life Sciences Corp. (HEAL)
Kategori
Healthcare
P/B-forhold for Restart Life Sciences Corp. (HEAL)
P/B-forhold per 2026 TTM: 0
Ifølge Restart Life Sciences Corp. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Restart Life Sciences Corp. fra 2026 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
